Literature DB >> 19969039

Accelerating response to antidepressant treatment in depression: a review and clinical suggestions.

Shinichiro Nakajima1, Takefumi Suzuki, Koichiro Watanabe, Haruo Kashima, Hiroyuki Uchida.   

Abstract

OBJECTIVE: The primary objective of this article is to review the literature regarding the speed of response to antidepressant drugs and potential strategies to accelerate the antidepressant response in new antidepressant-free patients with depression. Based on these data, we try to propose both an effective and safe antidepressant treatment strategy to alleviate depressive symptoms at the earliest opportunity. DATA SOURCES: Data were identified by searches of Medline (1966 to September 2009) and references from relevant articles and books. Search terms included depression, antidepressant, predictor, response, onset, acceleration, and augmentation. As our focus was on the acute phase treatment of depression, articles relevant to treatment-resistant depression were excluded. Only articles written in English or Japanese were consulted. DATA SELECTION: Studies, reviews, and books pertaining to the treatment of depression with a special regard to accelerating therapeutic effects were selected. DATA SYNTHESIS: Most of the available treatment guidelines for major depressive disorders recommend the continuous use of antidepressants for 4 to 8 weeks based on the idea of a delayed onset of response to these drugs. Contrary to this conventional belief, the recent data indicate that antidepressants start to exert their effects within 2 weeks and early non-response could predict a subsequent unfavorable outcome.
CONCLUSIONS: These findings suggest the need of revisiting the timing of an antidepressant switch for early non-responders, whereby switching could be commenced in as early as 2 weeks. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969039     DOI: 10.1016/j.pnpbp.2009.12.001

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  12 in total

1.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

2.  Improvement in depression scores after 1 hour of light therapy treatment in patients with seasonal affective disorder.

Authors:  Gloria M Reeves; Gagan Virk Nijjar; Patricia Langenberg; Mary A Johnson; Baharak Khabazghazvini; Aamar Sleemi; Dipika Vaswani; Manana Lapidus; Partam Manalai; Muhammad Tariq; Monika Acharya; Johanna Cabassa; Soren Snitker; Teodor T Postolache
Journal:  J Nerv Ment Dis       Date:  2012-01       Impact factor: 2.254

3.  Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data.

Authors:  Hitoshi Sakurai; Takefumi Suzuki; Kimio Yoshimura; Masaru Mimura; Hiroyuki Uchida
Journal:  Psychopharmacology (Berl)       Date:  2017-05-03       Impact factor: 4.530

4.  Creatine Prevents Corticosterone-Induced Reduction in Hippocampal Proliferation and Differentiation: Possible Implication for Its Antidepressant Effect.

Authors:  Francis L Pazini; Mauricio P Cunha; Dayane Azevedo; Julia M Rosa; André Colla; Jade de Oliveira; Ana B Ramos-Hryb; Patricia S Brocardo; Joana Gil-Mohapel; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2016-10-06       Impact factor: 5.590

Review 5.  [Cognitive deficits in unipolar major depression].

Authors:  C Konrad; S Losekam; M Zavorotnyy
Journal:  Nervenarzt       Date:  2015-01       Impact factor: 1.214

6.  High expectancy and early response produce optimal effects in sertraline treatment for post-traumatic stress disorder.

Authors:  Belinda Graham; Natalia M Garcia; Mark S Burton; Andrew A Cooper; Peter P Roy-Byrne; Matig R Mavissakalian; Norah C Feeny; Lori A Zoellner
Journal:  Br J Psychiatry       Date:  2018-10-25       Impact factor: 9.319

7.  Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response.

Authors:  Daniel E Casey; Kimberly K Laubmeier; Sabrina Vogel Marler; Robert A Forbes; Ross A Baker
Journal:  Prim Care Companion CNS Disord       Date:  2012-05-31

8.  Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study.

Authors:  Luis Molina; Byron Recinos; Bezner Paz; Mauricio Rovelo; Fanny Elizabeth Elias Rodriguez; José Calderón; Arturo Arellano; Santiago Pomata; María Verónica Rey; Santiago Perez-Lloret
Journal:  Clin Drug Investig       Date:  2016-06       Impact factor: 2.859

9.  Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway.

Authors:  Francis L Pazini; Mauricio P Cunha; Julia M Rosa; André R S Colla; Vicente Lieberknecht; Ágatha Oliveira; Ana Lúcia S Rodrigues
Journal:  Mol Neurobiol       Date:  2015-12-11       Impact factor: 5.590

10.  Antidepressant prescribing patterns in Korea: results from the clinical research center for depression study.

Authors:  Kyung-Yeol Bae; Sung-Wan Kim; Jae-Min Kim; Il-Seon Shin; Jin-Sang Yoon; Sung-Won Jung; Min-Soo Lee; Hyeon-Woo Yim; Tae-Youn Jun
Journal:  Psychiatry Investig       Date:  2011-08-26       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.